RO6864018
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 25, 2011
Anadys Highlights ANA773 Data to be Presented at ASCO
(PRNewswire)
- Anadys is currently preparing for a P2a trial of ANA773 in combination with ribavirin in HCV expected to begin in Europe in Q2'11; Anadys expects to receive 28-day data from P2a HCV study during Q4 '11
Anticipated P2 trial initiation • Hepatitis C Virus • Melanoma
1 to 1
Of
1
Go to page
1